MAIA Biotechnology, Inc.MAIAEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for hard-to-treat adult cancers. Its lead pipeline candidates target specific oncogenic pathways, operating primarily in North America's oncology market to address unmet medical needs for patients with limited treatment options.
MAIA Q3 FY2022 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.1M
Net Profit
$-4.9M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.48
MAIA Biotechnology, Inc. Q3 FY2022 Financial Summary
MAIA Biotechnology, Inc. reported revenue of $0 for Q3 FY2022, with a net profit of $-4.9M (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-4.9M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2022 |
Income Statement
| Q3 2022 | |
|---|---|
| Revenue | $0 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2022 | |
|---|---|
| Assets | $14.8M |
| Liabilities | $2.7M |
| Equity | $12.1M |
Cash Flow
| Q3 2022 | |
|---|---|
| Operating CF | $-4.3M |